{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26.3","upperLimit":"40.2","value":"33.0"},{"groupId":"OG001","lowerLimit":"50.0","upperLimit":"64.6","value":"57.4"},{"groupId":"OG002","lowerLimit":"41.6","upperLimit":"56.3","value":"48.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"188"},{"groupId":"OG002","value":"190"}],"units":"Participants"}],"description":"Percentage of participants achieving DC based on BICR assessment is presented in this endpoint. DC is a best overall response of CR (disappearance of all target lesions), PR (\\>=30% decrease under the baseline of the sum of diameters of all target measurable lesions), non-complete response/non-progressive disease or stable disease (SD) according to the RECIST version 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"NUMBER","populationDescription":"The secondary efficacy endpoint was analyzed in FAS. The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"Tumor assessments as assessed by investigator were conducted at every 8 weeks from screening until documented disease progression, up to 30 months; based on cutoff date: 19 September 2018.","title":"Disease Control (DC) Rate Based on BICR Assessment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}